What the business is, and whether it's a good one at a fair price.
A Finance company listed on BSE, reporting revenue of ₹1 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Other Financial Services peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from BIOGEN PHARMACHEM INDUSTRIES L's filed financials and exchange disclosures
BIOGEN PHARMACHEM INDUSTRIES L is a Finance company listed on BSE.
No. Over the trailing twelve months BIOGEN PHARMACHEM INDUSTRIES L reported a net loss of ₹0 Cr on revenue of ₹1 Cr.
Not in the latest reported year — BIOGEN PHARMACHEM INDUSTRIES L's dividend payout for FY26 was nil.
Effectively yes. It holds ₹0 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, BIOGEN PHARMACHEM INDUSTRIES L ranks 38 of 95 in Other Financial Services — cheaper than 61% of them, against an industry median of 17.9×. This is a position, not a valuation judgement.
On a typical session BIOGEN PHARMACHEM INDUSTRIES L moves 1.61% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by BIOGEN PHARMACHEM INDUSTRIES L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
